Compare RAY & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAY | CVKD |
|---|---|---|
| Founded | 1993 | 2022 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 13.8M |
| IPO Year | 2022 | 2022 |
| Metric | RAY | CVKD |
|---|---|---|
| Price | $3.71 | $5.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 9.8K | ★ 57.5K |
| Earning Date | 07-24-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $4.21 |
| 52 Week High | $5.49 | $15.99 |
| Indicator | RAY | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 62.45 | 49.60 |
| Support Level | $3.24 | $5.15 |
| Resistance Level | $3.78 | $6.09 |
| Average True Range (ATR) | 0.22 | 0.56 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 88.80 | 34.14 |
Raytech Holding Ltd is principally engaged in product designing and manufacturing of various product ranges such as Hair Care, Men's Care and Women's Care products. It has sourced and wholesaled a wide range of personal care electrical appliances, which can be broadly classified into seven categories: hair styling series, including hair dryer, hair straightener and curling iron; trimmer series, including facial shaver, nose trimmer and eyebrow trimmer; eyelash curler; neck care series; nail care series; tooling and other personal care appliances such as body and facial brush, reset brush, callus remover, sonic peeling, handy fan and others. Raytech manufactures products under OEM and ODM.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.